Cryoablation with immunotherapy and targeted therapy for advanced bile duct cancer
Part of Cancer clinical trials.
This trial tests a combination of freezing the tumor (cryoablation), an experimental immunotherapy (SHR-1701), and a targeted therapy pill (famitinib) for people with advanced bile duct cancer that has progressed after standard treatment. The goal is to see if this combination can shrink tumors or slow the cancer's growth.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- You have a diagnosis of intrahepatic cholangiocarcinoma that cannot be removed with surgery or has spread to other parts of the body.
- You have already tried one line of the standard chemo-immunotherapy (gemcitabine, cisplatin, and a PD-1/PD-L1 inhibitor) and it failed or caused severe side effects.
- You have at least one tumor that can be measured on a CT scan or MRI.
- You are generally active (able to care for yourself) and have a life expectancy of at least 3 months.
- Your blood counts, liver function, and kidney function are within acceptable levels.
- You have not had cryoablation before.
- You have not had a major bleeding episode in the last 4 weeks, and no blood clots in the last 6 months (unless it's a clot in a small portal vein branch).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of two immunotherapy drugs with chemotherapy for people with advanced bile duct cancer that cannot be removed by surgery or has spread. The goal is to see if this combination can help shrink tumors or slow the cancer's growth.
This trial tests a procedure called cryoablation, which freezes and destroys cancer cells, combined with a targeted therapy drug (anlotinib) for people with advanced bile duct cancer that has not responded to earlier treatments. The goal is to see if this combination can slow the cancer's growth and improve outcomes.
This trial tests a combination of cryoablation (freezing tumors), lenvatinib (a targeted therapy), and QL1706 (an immunotherapy) for people with advanced intrahepatic cholangiocarcinoma (bile duct cancer) that has worsened after initial treatment. The goal is to see if this combination can help stop the cancer from growing.
This trial tests whether a combination of cryoablation (freezing tumors) and two drugs (lenvatinib and tislelizumab) works better than a standard chemotherapy regimen (FOLFOX) for people with advanced intrahepatic cholangiocarcinoma (a type of bile duct cancer in the liver) that has not responded to or has stopped responding to one prior therapy.
This Phase 2 trial tests whether freezing part of the liver tumor (cryoablation) combined with an immunotherapy drug called anti–PD-1 can shrink advanced bile-duct cancer that can’t be removed by surgery. It may help control the cancer after prior treatments have stopped working.
This study tests a combination of freezing the tumor (cryoablation), an investigational immunotherapy (QL1706), and a targeted therapy pill (lenvatinib) for people with advanced bile duct cancer that has progressed after initial treatment. The goal is to see if this new combination can help control the cancer and improve outcomes.
Hear when a new Advanced Intrahepatic Cholangiocarcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.